|
|
Volumn 30, Issue 7, 2012, Pages 577-
|
|
Debate over details of US biosimilar pathway continues to rage.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOSIMILAR AGENT;
CLINICAL TRIAL (TOPIC);
DRUG INDUSTRY;
ECONOMICS;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LEGAL ASPECT;
NOTE;
UNITED STATES;
BIOSIMILAR PHARMACEUTICALS;
CLINICAL TRIALS AS TOPIC;
DRUG INDUSTRY;
HUMANS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84871857311
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0712-577 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|
